BioNTech Shares Face Scrutiny Ahead of Earnings Release

Investor focus is firmly on BioNTech as the biotech firm prepares to release its full-year 2025 financial results this coming Tuesday. The prevailing mood in the markets, however, is one of caution rather than anticipation, underscored by a recent share price decline that has breached key technical levels. The central issue for shareholders is whether the company’s robust oncology pipeline can offset declining Covid-19 vaccine revenues with sufficient speed.

A Substantial Strategic Shift

BioNTech’s transition is backed by formidable financial resources. Despite revenue headwinds, the company concluded 2025 with a substantial cash position of €17.2 billion. This war chest is earmarked to fund the costly strategic pivot from a vaccine specialist to a broader oncology-focused therapeutics developer.

The roadmap for this transformation is clear. Management views 2026 as a pivotal transition year, marked by an accelerated pace. The company plans seven data readouts from late-stage trials, five of which hold potential for eventual regulatory approval. A key objective is to have 15 Phase 3 studies active by year-end, targeting cancers including lung and breast cancer.

The Revenue Challenge in Focus

When BioNTech presents its figures on March 10, guidance will be under the microscope. Management’s previous revenue forecast for the year sits in a range of €2.6 to €2.8 billion. These figures highlight a steep drop from the pandemic-era peak, driven by waning global demand for the Comirnaty Covid-19 vaccine and shifts in vaccination guidelines, particularly in the United States.

The company anticipates a further slight decline in 2026 as the vaccine market increasingly shifts to the private commercial sector. Revenue contributions from new cancer drug sales are not projected for the current year.

Should investors sell immediately? Or is it worth buying BioNTech?

Pipeline Developments Offer Operational Positives

Operational progress has been notable, even if the equity market has not rewarded it. A significant milestone was the U.S. FDA granting Fast Track designation to the drug candidate BNT113 for treating certain head and neck cancers—an area of high unmet medical need.

Furthermore, a $1.5 billion payment from the collaboration with Bristol Myers Squibb bolstered the balance sheet. The strategic expansion through the acquisition of CureVac, finalized in December, is also now complete.

Mixed Signals from the Market and Analysts

Market reaction to recent developments has been tepid. The stock, closing at €87.50, has shed over 6% on a weekly basis and traded below its 200-day moving average of €89.92—a technical breakdown that often prompts caution among traders.

Analyst opinions are divided. While Goldman Sachs recently commended the execution of the company’s plans, the research firm Leerink downgraded the stock, citing limited upside potential following a prior recovery. The upcoming financial report on Tuesday will need to provide concrete signals from management capable of dispelling the current market skepticism.